Auro Laboratories Ltd

Auro Laboratories Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has recently formed a Golden Cross—a significant technical indicator where the 50-day moving average (DMA) has crossed above the 200-DMA. This development signals a potential bullish breakout and a long-term momentum shift, suggesting renewed investor confidence and a possible trend reversal in the stock’s trajectory.

Auro Laboratories Ltd has reached a new 52-week and all-time high of Rs.317, reflecting a robust rally in the Pharmaceuticals & Biotechnology sector. This milestone underscores the stock’s strong momentum, outperforming its sector peers and the broader market over the past year.

Auro Laboratories Ltd has reached a significant milestone by hitting an all-time high in its stock price, reflecting a sustained period of strong performance within the Pharmaceuticals & Biotechnology sector. The stock’s recent surge underscores the company’s resilience and market strength as it outpaces key benchmarks and trading averages.

Auro Laboratories Ltd achieved a significant milestone on 12 Feb 2026, reaching a new 52-week high of Rs.308.9. This marks a notable peak in the stock’s performance, reflecting sustained momentum over the past year within the Pharmaceuticals & Biotechnology sector.

Auro Laboratories Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs.308.9 on 12 Feb 2026, underscoring a remarkable period of sustained growth and robust market performance.

Auro Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting significant improvements across financial performance, valuation metrics, and technical indicators. The pharmaceutical company’s recent quarterly results and sustained market outperformance have driven this reassessment, signalling a more favourable outlook amid a challenging sector environment.

Auro Laboratories Ltd., a Mumbai-based generic Active Pharmaceutical Ingredients (API) manufacturer specialising in anti-diabetic compounds, reported a dramatic revenue recovery in Q2 FY26, with net sales surging 219.13% quarter-on-quarter to ₹8.84 crores. However, the micro-cap pharmaceutical company's consolidated net profit of ₹0.72 crores, whilst representing a turnaround from the previous quarter's loss of ₹0.11 crores, reflects an unusual tax rate of 58.14% that significantly compressed profitability. Following the results, the stock rallied 4.35% to ₹265.00 on February 5, 2026, though the company's market capitalisation remains modest at ₹156.00 crores.

Auro Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 03 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Auro Laboratories Ltd has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 29 Dec 2025, reflecting a deterioration in its technical outlook alongside persistent financial challenges. The company’s Mojo Score has declined to 41.0, signalling caution for investors amid flat quarterly results, weak debt servicing ability, and a sideways technical trend.

Auro Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its market evaluation following recent changes in its technical outlook and financial performance. While the company’s long-term returns remain impressive compared to broader market indices, mixed signals from valuation metrics and financial trends have influenced the latest assessment of its investment profile.

Auro Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators, including valuation concerns and subdued financial trends, which continue to shape investor perspectives.

Auro Laboratories Ltd has witnessed extraordinary buying momentum today, registering a sharp surge that propelled the stock to hit its upper circuit limit. The absence of sellers and a queue filled exclusively with buy orders signal a potential multi-day circuit scenario, underscoring robust investor interest in this Pharmaceuticals & Biotechnology company.